Aggressive t cell lymphomas, integrated clinical and genomic analysis for a precision medicine.
Lymphoid leukemias and lymphomas represent frequent areas of the tumour pathology. Recent Integrative clinical and molecular studies allows to identify concrete disorders where a precise recognition leads to a specific treatment with a minimum toxicity and maximum clinical benefit. Even though there have been many progress during last years, there still persist numerous conditions with low survival probability and high side effects of the received treatments. 

The introduction of the precision medicine in lymphoid neoplasms is new and challenging due to the scarce knowledge about disease pathogenesis, targeted therapies and predictor markers, immunotherapy role and poor experimental models.

T-cell lymphoma tumors present a dismal survival probability dismal (25% for Peripheral T-cell lymphoma) in patients, and the molecular mechanism underlying their high rate of lack response to treatments and relapse is poorly understood.  Furthermore, patients with lymphoproliferative disorders often have complex (multiclonal) or mixed lymphoproliferative disorders.

This project aim the consolidation of the precision medicine in the diagnosis and therapy of these disorders, thus facilitating the treatment of each patient according its disease, with specific therapy according to the integral characterization of its disease, thus reducing toxicity and improving the therapy efficacy.

The project focuses on complex lymphoproliferative diseases characterized by clinical aggressiveness with low therapeutic response, tumor heterogeneity and patterns of dependency / interaction with the microenvironment. The success of the project requires in first instance to improve in the knowledge of the molecular basis of the disease and subsequently in the identification of precise tumour types and patient stratification, thus facilitating the identification of markers for targeted therapy, using gene expression and mutational signatures.